May 12, 2014 9:21 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
In a report published Monday, Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating on
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
(NASDAQ: AMGN), but removed the $140.00 price target.In the report, Morgan Stanley noted, “The AMAGINE-1 study is the 1st of three PhIII studies for brodalumab (AMAGINE-2 & 3 are head-to-head comparisons with Stelara). The two studied doses (210mg and 140mg) achieved statically significant PASI 75 (83.3% and 60.3% v 2.7%), PASI 90 (70.3% and 42.5% v 0.9%) and PASI 100 (41.9% and 28.7% v 0.5%) reductions vs placebo. Serious AEs were balanced (1.8% for 210mg, 2.7% for 140mg and 1.4% for pbo) with headaches and colds the most common AEs.”Amgen closed on Friday at $111.48.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.